Paroxetine in Social Phobia
J Clin Psychiatry 1996;57(11):519-522
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Several open trials suggest the efficacy of the selective serotonin reuptake inhibitors (SSRIs) in social phobia. This study attempted to assess the efficacy of paroxetine, a new SSRI, in the treatment of social phobia.
Method: Paroxetine was administered to 18 patients who had a primary DSM-III-R diagnosis of social phobia, generalized type (diagnosed by using the Structured Clinical Interview for DSMIII- R), in a 12-week open, clinical trial. Treatment began at 10 mg of paroxetine daily and was increased according to clinical response and side effects. Patients completed self-report measures at baseline and at Weeks 4, 8, and 12. These measures included the Fear of Negative Evaluation Scale, the Social Avoidance and Distress Scale, the Social Anxiety Thoughts Questionnaire, the Fear Questionnaire, the State-Trait Anxiety Inventory, the Beck Depression Inventory, the Social Adjustment Scale Self-Report, and the Sheehan Disability Scale. Clinicians completed the Liebowitz Panic and Social Phobic Disorders Rating Form.
Results: All 18 patients completed the 12-week trial. Fifteen (83.3%) were considered responders (moderate or marked improvement), and 3 (16.7%) were considered to be nonresponders (minimal improvement or no change of their symptoms). All measures of social anxiety, social phobic avoidance, depression, and social functioning showed a statistically significant change at endpoint.
Conclusion: These findings support a role for paroxetine in the treatment of social phobia, generalized type. Controlled studies will be required to further investigate this preliminary finding as well as to compare paroxetine with other pharmacologic treatments of social phobia.